A phase 1/2 clinical trial has shown a potential therapeutic impact of TLR9 inhibition on ABC DLBCL bearing MYD88 L265P mutation targeting TLR9 by an inhibitor referred as IMO-8400 in patients with relapsed or refractory DLBCL. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.